Breast Cancer Clinical Trial

Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment

Summary

The purpose of this clinical trial is to determine if the investigational drug is able to reduce/shrink advanced breast cancer tumors in patients who no longer benefit from anthracyclines, taxanes and capecitabine.

View Full Description

Full Description

All patients in this trial will receive the investigational (chemotherapy) drug at an optimal dose as determined by previous clinical trials. The investigational drug is given through a vein once every three weeks. This drug prevents tumor cells from dividing, so they may stop growing or die.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

In order to be eligible for this trial you must:

Have a diagnosis of breast cancer that is now metastatic (meaning the cancer has spread beyond its original location) or a recurrence of the cancer in its original location that cannot be removed by surgery.
Have received previous treatment with anthracyclines (e.g. doxorubicin [Adriamycin or Doxil] or epirubicin [Ellence]), taxanes (paclitaxel [Taxol or Abraxane] or docetaxel [Taxotere]) and capecitabine (e.g. Xeloda) for your breast cancer and your doctor has determined that these treatments are no longer of benefit to you.
Be at least 18 years of age
Not be taking other treatments for your cancer at the time you enter the trial.
Not be pregnant
Additionally, there are other criteria for study entry that a doctor participating in this study will need to review in detail with you and clinical assessments may need to be performed (lab tests, CT scans).

Exclusion Criteria:

None listed here. Can be discussed with your doctor.

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

168

Study ID:

NCT00087958

Recruitment Status:

Completed

Sponsor:

Sanofi

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Sanofi-Aventis Administrative Office
Bridgewater New Jersey, 08807, United States
Sanofi-Aventis Administrative Office
Buenos Aires , , Argentina
Sanofi-Aventis Administrative Office
Diegem , , Belgium
Sanofi-Aventis Administrative Office
Laval , , Canada
Sanofi-Aventis Administrative Office
Santafe de Bogota , , Colombia
Sanofi-Aventis Administrative Office
Horsholm , , Denmark
Sanofi-Aventis Administrative Office
Paris , , France
Sanofi-Aventis Administrative Office
Berlin , , Germany
Sanofi-Aventis Administrative Office
Milano , , Italy
Sanofi-Aventis Administrative Office
Seoul , , Korea, Republic of
Sanofi-Aventis Administrative Office
Gouda , , Netherlands
Sanofi-Aventis Administrative Office
Midrand , , South Africa
Sanofi-Aventis Administrative Office
Barcelona , , Spain
Sanofi-Aventis Administrative Office
Geneva , , Switzerland
Sanofi-Aventis Administrative Office
Istanbul , , Turkey

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

168

Study ID:

NCT00087958

Recruitment Status:

Completed

Sponsor:


Sanofi

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.